HOMEPRODUCTSSERVICESCOMPANYCONTACTFAQResearchDictionaryPharmaMobileSign Up FREE or Login

[New therapeutic alternatives in migraine prophylaxis using histamine H3 receptor agonists].

AbstractBACKGROUND:
Subcutaneous histamine at low concentrations interacts with H3-receptors and may constitute a new therapeutic drug in migraine prophylaxis. It acts by limiting the excessive inflammatory response involved in migraine pathophysiology.
OBJECTIVE:
Describe the results of a 15-year trial administering histamine at low concentrations.
METHODS:
Different study designs were used with subcutaneous histamine (10 microg/ml in Evan's solution) twice weekly, with an initial administration of microg (0.1 ml) and gradually increasing the dose to 10 microg (1.0 ml) over a 12-week period together with placebo, sodium valproate and topiramate. A Friedman-type rank ANOVA test was used to assess the difference between basal values and different design outcomes.
RESULTS:
Data recorded during the 12-week period showed a significant reduction in variables from both treatment groups (histamine) compared with basaline stage results (p < 0.001). The histamine group reported a reduction of headache frequency (50%), decrease in pain intensity (51%), length of migraine attacks (45%) and painkiller use (52%).
CONCLUSIONS:
The present study provides evidence on the safety and efficiency of subcutaneous histamine administered at a dose of 1-10 microg twice weekly. This treatment constitutes a new therapeutic alternative, and provides a clinical and pharmacological basis for the use of H3 histaminergic agonists in migraine prophylaxis.
AuthorsRebeca O Millán-Guerrero, Rebeca Isais-Millán
JournalGaceta médica de México (Gac Med Mex) 2008 Jul-Aug Vol. 144 Issue 4 Pg. 291-5 ISSN: 0016-3813 [Print] Mexico
Vernacular TitleNueva alternativa terapéutica en profilaxis de migraña con histamina como agonista de receptores H3.
PMID18942262 (Publication Type: English Abstract, Journal Article)
Chemical References
  • Histamine Agonists
Topics
  • Adult
  • Female
  • Histamine Agonists (therapeutic use)
  • Humans
  • Male
  • Migraine Disorders (prevention & control)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!


Choose Username:
Email:
Password:
Verify Password: